VANCOUVER, Sept. 23, 2019 /PRNewswire/ - Neovasc Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara ("Tiara") transcatheter mitral valve replacement device and its Neovasc Reducer ("Reducer") CE-Marked device for the treatment of refractory angina will be featured in multiple presentations at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 scientific symposium, which takes placeSeptember 25-29, 2019,inSan Francisco.
"We are excited that our core products, Tiara and Reducer, will be prominently featured at TCT, the largest and most prestigious interventional cardiology conference in North America," said Fred Colen, President and Chief Executive Officer of Neovasc. "Our team looks forward to interacting with many of the leading cardiologists from around the globe."
Select Presentations:
Tiara
Reducer
About TiaraTiara is a self-expanding mitral bioprosthesis specifically designed to treat mitral valve regurgitation ("MR") by replacing the diseased valve. Conventional surgical treatments are only appropriate for about half of MR patients, who number an estimated four million in the U.S. with a similar number of patients affected throughoutEurope. Tiara is implanted in the heart using a minimally invasive, transapical transcatheter approach without the need for open-heart surgery or use of a cardiac bypass machine.
The Tiara valve is currently being evaluated in two ongoing clinical trials: TIARA-Ian early feasibility trial inthe United States,Canada, andBelgium; and TIARA-IIa European Conformit EuropenneMark TrialinGermany,Italy,Spain, and theUnited Kingdom. In addition, patients have also been treated under compassionate programs inCanada,Italy,Germany,Israel, andSwitzerland.
About ReducerThe Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow in the heart's circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and is completed in approximately 20 minutes.
While the Reducer is not approved for commercial use in theUSA, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Device designation to the Neovasc Reducer inOctober 2018. This designation is granted by the FDA in order to expedite the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. In addition, there must be no FDA approved treatments presently available, or the technology must offer significant advantages over existing approved alternatives.
Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, is estimated to affect 600,000 to 1.8 million Americans, with 50,000 to 100,000 new cases per year.1
About Neovasc Inc.Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently commercially available inthe United Statesand has been commercially available inEuropesince 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation inthe United States,CanadaandEurope. For more information, visit:www.neovasc.com.
Forward-Looking Statement DisclaimerCertain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Forward-looking statements may involve, but are not limited to, statements regarding the growing incidence of refractory angina and the growing cardiovascular marketplace. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, risks relating to the possibility that the Company's common shares may be delisted from the Nasdaq Capital Market or the Toronto Stock Exchange, including Nasdaq's discretionary public interest authority to apply more stringent criteria for continued listing or suspend or delist securities, which could affect their market price and liquidity; the substantial doubt about the Company's ability to continue as a going concern; risks relating to the senior secured convertible notes (the "Notes") issued pursuant to theNovember 2017private placement (the "2017 Financing"), resulting in significant dilution to the Company's shareholders; risks relating to the Company's need for significant additional future capital and the Company's ability to raise additional funding; risks relating to cashless exercise and adjustment provisions in the Notes issued pursuant to the 2017 Financing, which could make it more difficult and expensive for the Company to raise additional capital in the future and result in further dilution to investors; risks relating to the sale of a significant number of common shares of the Company; risks relating to the conversion of the senior secured convertible Notes issued pursuant to the 2017 Financing, which may encourage short sales by third parties; risks relating to the Company's conclusion that it did not have effective internal control over financial reporting as atDecember 31, 2018; risks relating to the Company's Common Share price being volatile; risks relating to the influence of significant shareholders of the Company over the Company's business operations and share price; risks relating to the Company's significant indebtedness, and its effect on the Company's financial condition; risks relating to claims by third parties alleging infringement of their intellectual property rights; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the payment of significant damages and other remedies; the Company's ability to establish, maintain and defend intellectual property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; the Company's history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more of the Company's competitors may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks associated with the extensive regulation of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation of the Company's products; health and safety risks associated with the Company's products and industry; risks associated with the Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risk of animal disease associated with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks associated with future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; the Company's ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks associated with consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to the Company's ability to successfully enter into fundamental transactions as defined in the Notes issued pursuant to the 2017 Financings; anti-takeover provisions in the Company's constating documents which could discourage a third party from making a takeover bid beneficial to the Company's shareholders; and risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three and six months endedJune 30, 2019(copies of which may be obtained atwww.sedar.comorwww.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.
1T. J. Povsic, S. Broderick, K. J. Anstrom et al., "Predictors of longterm clinical endpoints in patients with refractory angina," Journal of the American Heart Association, vol. 4, no. 2, article e001287, 2015.
View original content:http://www.prnewswire.com/news-releases/tiara-for-treatment-of-mitral-regurgitation-and-neovasc-reducer-for-treatment-of-refractory-angina-to-be-featured-at-tct-2019-conference-300922912.html
SOURCE Neovasc Inc.
Continued here:
- Interventional Cardiology Fellowship - Massachusetts General Hospital ... - April 8th, 2018 [April 8th, 2018]
- Dr. Eric Lo - Daytona Beach FL, Interventional Cardiology - April 18th, 2018 [April 18th, 2018]
- Interventional Cardiology | Cardiology Associates of East ... - April 19th, 2018 [April 19th, 2018]
- ECU Interventional Cardiology Fellowship - May 26th, 2018 [May 26th, 2018]
- Interventional Cardiology | Knoxville Heart Group - June 6th, 2018 [June 6th, 2018]
- Interventional Cardiology Fellowship - Massachusetts ... - June 14th, 2018 [June 14th, 2018]
- Scottsdale Interventional Forum | Cardiology Conference ... - June 21st, 2018 [June 21st, 2018]
- Interventional Cardiology - Terumo Europe - August 12th, 2018 [August 12th, 2018]
- Interventional Cardiology Fellowship | Cardiovascular Fellowship - September 20th, 2018 [September 20th, 2018]
- Interventional > Cardiovascular Medicine | Internal Medicine ... - September 20th, 2018 [September 20th, 2018]
- Interventional Cardiology Journal | Peer reviewed Journal - September 24th, 2018 [September 24th, 2018]
- Interventional Cardiology | North Florida Regional Medical ... - October 4th, 2018 [October 4th, 2018]
- Interventional Cardiology | Department of Medicine ... - October 4th, 2018 [October 4th, 2018]
- Interventional Cardiology | Medical City Fort Worth - October 4th, 2018 [October 4th, 2018]
- Cardiology and Interventional Cardiology | Texas Tech ... - October 4th, 2018 [October 4th, 2018]
- Invasive & Interventional Cardiology Section | Cleveland Clinic - October 4th, 2018 [October 4th, 2018]
- Interventional Cardiology - Crozer-Keystone Health System - PA - October 4th, 2018 [October 4th, 2018]
- Interventional Cardiology - Florida Medical Clinic - October 4th, 2018 [October 4th, 2018]
- Interventional Cardiology | Heart Hospital of New Mexico - October 4th, 2018 [October 4th, 2018]
- Interventional Cardiology | ColumbiaDoctors - October 4th, 2018 [October 4th, 2018]
- Interventional Cardiologist Jobs | Glassdoor - October 4th, 2018 [October 4th, 2018]
- What are Invasive, Non-Invasive, and Interventional Cardiology? - October 4th, 2018 [October 4th, 2018]
- Interventional Cardiology Fellowship | Internal Medicine - October 25th, 2018 [October 25th, 2018]
- Interventional Cardiology | Community Health Network - October 25th, 2018 [October 25th, 2018]
- Interventional Cardiology | Ohio State Medical Center - October 25th, 2018 [October 25th, 2018]
- Interventional Cardiology | Stanford Health Care - October 25th, 2018 [October 25th, 2018]
- Interventional Cardiology - Montefiore Medical Center - November 10th, 2018 [November 10th, 2018]
- Interventional Cardiologists near Brooklyn, NY - Healthgrades - November 10th, 2018 [November 10th, 2018]
- Cardiac Catheterization | Interventional Cardiology in New ... - November 20th, 2018 [November 20th, 2018]
- What are Invasive, Non-Invasive, and Interventional ... - November 27th, 2018 [November 27th, 2018]
- Dr. Jaffar A Raza - Secaucus NJ, Interventional Cardiology - November 30th, 2018 [November 30th, 2018]
- Interventional cardiology - Wikipedia - December 13th, 2018 [December 13th, 2018]
- Interventional Cardiology | St. Francis - December 21st, 2018 [December 21st, 2018]
- Interventional Cardiologists near Secaucus, NJ - Healthgrades - December 21st, 2018 [December 21st, 2018]
- Interventional Cardiology Conferences & Meetings - December 25th, 2018 [December 25th, 2018]
- Interventional Cardiology - Baylor Heart and Vascular Hospital - January 18th, 2019 [January 18th, 2019]
- Interventional Cardiology - nationwidechildrens.org - January 18th, 2019 [January 18th, 2019]
- General & Interventional Cardiology - WakeMed - January 18th, 2019 [January 18th, 2019]
- Interventional Cardiology - University of Mississippi Medical ... - January 18th, 2019 [January 18th, 2019]
- Interventional Cardiologists in Austin, TX | Austin Heart - February 22nd, 2019 [February 22nd, 2019]
- Interventional Cardiology | Sutter Health - February 22nd, 2019 [February 22nd, 2019]
- Interventional Cardiology - St. Mary's Hospital and Health ... - February 22nd, 2019 [February 22nd, 2019]
- London & Milan - Cardiology Fellowships - February 22nd, 2019 [February 22nd, 2019]
- Interventional Cardiology | Saint Luke's Health System - February 22nd, 2019 [February 22nd, 2019]
- Interventional Cardiology | American Medical Association - February 22nd, 2019 [February 22nd, 2019]
- Interventional Cardiology | Piedmont Heart Institute ... - March 12th, 2019 [March 12th, 2019]
- Interventional Cardiology | UCSF Cardiology - March 18th, 2019 [March 18th, 2019]
- If You Are Referred to an Interventional Cardiologist - April 1st, 2019 [April 1st, 2019]
- Cardiology and Interventional Medicine | Veterinary ... - April 5th, 2019 [April 5th, 2019]
- Interventional Cardiology | AdventHealth Cardiovascular ... - May 11th, 2019 [May 11th, 2019]
- APSIC - Asian Pacific Society of Interventional Cardiology - May 13th, 2019 [May 13th, 2019]
- Interventional Cardiology | UNC REX Healthcare | Raleigh ... - May 20th, 2019 [May 20th, 2019]
- Interventional Cardiology - montefiore.org - May 20th, 2019 [May 20th, 2019]
- Women and heart health: Heart attack signs and symptoms to know about - The Indian Express - September 26th, 2019 [September 26th, 2019]
- Tiara for Treatment of Mitral Regurgitation and Neovasc Reducer for Treatment of Refractory Angina to be Featured at TCT 2019 Conference - Canada... - September 26th, 2019 [September 26th, 2019]
- TherOx to Present on SuperSaturated Oxygen (SSO2) at TCT2019 Next Week - BioSpace - September 26th, 2019 [September 26th, 2019]
- Too tired? it can indicate heart failure - The New Indian Express - September 26th, 2019 [September 26th, 2019]
- Blue Sail Medical and Biosensors International enter the Structural Heart market with the acquisition of Switzerland based NVT AG. content= - PR... - September 26th, 2019 [September 26th, 2019]
- Global Diagnostic Interventional Cardiology Instruments Market forecast by 2025 : Numerous tactics accepted by industry participants in a bid to... - September 26th, 2019 [September 26th, 2019]
- UMA's Complete Conference Management Hosts "Full Spectrum of Heart Failure Therapy: Optimizing Outcomes" - Yahoo Finance - September 26th, 2019 [September 26th, 2019]
- Meet the best cardiologists at King's Interactive Heart Health Morning - Gulf News - September 26th, 2019 [September 26th, 2019]
- Lights, camera, action in Varnville - Bluffton Today - September 26th, 2019 [September 26th, 2019]
- Health Pro: Cardiologist takes pleasure in getting patients back on their feet - Florida Today - September 26th, 2019 [September 26th, 2019]
- From Ceiling Suspension to Eye-Tracking: Innovation Continues for Cath Lab Radiation Protection - TCTMD - September 26th, 2019 [September 26th, 2019]
- Robocath Successfully Carries Out Its First Robotic Coronary Angioplasties in Humans - TCTMD - September 26th, 2019 [September 26th, 2019]
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ABIOMED, Inc. of Class Action Lawsuit and Upcoming... - September 28th, 2019 [September 28th, 2019]
- Study links childhood obesity with screen time - The Hindu - September 28th, 2019 [September 28th, 2019]
- Five Atlantic Health System Team Members Lauded by NJ American Heart Association for Life-Saving Measures - TAPinto.net - September 28th, 2019 [September 28th, 2019]
- World Heart Day 2019: Cardiovascular Disease Is The World's Biggest Killer And Claims More Than 17.5 Million Lives - Outlook India - September 28th, 2019 [September 28th, 2019]
- Consulting Cardiologists Brings Exceptional Care to Heart of WH - Patch.com - September 28th, 2019 [September 28th, 2019]
- Diagnostic Interventional Cardiology Devices Market 2019| Global Forecast to 2026 with Key Players- B. Braun Medical, Boston Scientific, Cook Medical,... - September 28th, 2019 [September 28th, 2019]
- Surmodics Inc. (SRDX) and Its Competitors Comparing side by side. - MS Wkly - October 17th, 2019 [October 17th, 2019]
- Global Price, Sales and Revenue Analysis of Diagnostic Interventional Cardiology Devices Market by Regions, Manufacturers, Types and Applications -... - October 17th, 2019 [October 17th, 2019]
- Global Interventional Cardiology Devices Market Study by Price, Type and Application, Statistical Forecast and Competitive Landscape Research upto... - October 17th, 2019 [October 17th, 2019]
- Global Interventional Cardiology Market Report, Trends, CAGR Standing, Analysis and Forecasts (2019-2025) | Key Companies BIOTRONIK SE & Co.... - October 17th, 2019 [October 17th, 2019]
- Interventional Cardiology Market 2019 to Flourish with an Impressive CAGR of XX% in the year 2024, Predicts Market Research Future According to... - October 17th, 2019 [October 17th, 2019]
- FDA Approves Coronary ViperWire Advance With Flex Tip - Diagnostic and Interventional Cardiology - October 23rd, 2019 [October 23rd, 2019]
- Teleflex Announces Third Quarter 2019 Earnings Conference Call Information Live Webcast is scheduled at 8:00 am (ET) on Thursday, October 31, 2019 -... - October 23rd, 2019 [October 23rd, 2019]
- Global Interventional Cardiology Devices Market Analysis and CAGR during the Forecasting years of 2019-2025. - Air News Paper - October 23rd, 2019 [October 23rd, 2019]
- Interventional Cardiology and Peripheral Vascular Devices Market Outlook : Business Overview, Industry Insights, Upcoming Trends and Top Company... - October 23rd, 2019 [October 23rd, 2019]